Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043322 | 0.93 | KMT2A (0.39) | HCN4ITGB1ITGA4ITGB7FAAH | |
| SCHEMBL4212749 | 0.91 | P2RX7 (0.35) | P2RX7HCN4KCNA3TSHRTAS1R3 | |
| SCHEMBL4209748 | 0.83 | FAAH (0.37) | ITGB1ITGA4FAAHCNR2TSHR | |
| SCHEMBL4215610 | 0.83 | HTT (0.38) | ITGB1ITGA4FAAHCNR2ALDH1A1 | |
| SCHEMBL4039303 | 0.83 | HCN4 (0.34) | HCN4MEN1KMT2AALDH1A1 | |
| SCHEMBL4212745 | 0.79 | ABCB1 (0.40) | P2RX7 | |
| SCHEMBL4215035 | 0.77 | HPGD (0.37) | TSHRKMT2AALDH1A1POLB | |
| SCHEMBL4211507 | 0.77 | P2RX7 (0.38) | P2RX7TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL4212824 | 0.76 | NPC1 (0.38) | FAAHCNR2TSHRKMT2ATAS1R3 | |
| SCHEMBL6539769 | 0.76 | TP53 (0.38) | HCN4FAAHCNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | claimed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | claimed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | claimed |
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | claimed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | claimed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | claimed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | RHEOGENE, INC. (DE CORPORATION) | 2004-09-02 | — | — | US | claimed |
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-09-28 | — | — | US | disclosed |
| US-9677055-B2 | Modified forms of Pseudomonas exotoxin A | INTERXON CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170037386-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-02-09 | — | — | US | disclosed |
| US-9447387-B2 | Modified forms of pseudomonas exotoxin A | INTREXON CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9371517-B2 | Modified forms of Pseudomonas exotoxin A | INTREXON CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160108377-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2016-04-21 | — | — | US | disclosed |
| US-20150291941-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2013036574-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | P2RX7 4099/4885HCN4 4860/4885KCNA3 3962/4885 |
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | CD4, CD47, CD14 | P2RX7 2615/4885HCN4 4040/4885KCNA3 1375/4885 |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | P2RX7 4099/4885HCN4 4860/4885KCNA3 3962/4885 |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | NR2E3, ESRRB, NR0B2 | P2RX7 4495/4885HCN4 4821/4885KCNA3 3532/4885 |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | ESRRB, NR2E3, NR5A1 | P2RX7 4125/4885HCN4 4859/4885KCNA3 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.